Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dan Zabrowski, Bary Bailey, Earl Collier, Dwight Crane, and more

Premium


Roche Diagnostics
has appointed Dan Zabrowski as head of Roche Applied Science, in the company's diagnostics division in Penzberg, Germany. He succeeds Paul Brown who has led Roche Applied Science since September. He will report to Daniel O'Day, chief operating officer of Roche Diagnostics.


In line with its hostile bid to acquire Illumina (IS 1/31/2012), Roche has nominated six individuals for election to the company's board of directors.

Bary Bailey is the president of 4B Management and an operating partner at Cressey & Company. Previously, he served as chief financial officer at AMN Healthcare Services and also as executive vice president and chief financial officer of Valeant Pharmaceuticals International. He is a certified public accountant and holds a BS in accounting from California State University.

Earl Collier has served as executive chairman of Arsenal Medical, CEO of 480 Biomedical, and as a senior advisor to Polaris Venture Partners since 2010. Previously, he was executive vice president of Genzyme, interim CEO of Decode Genetics, and president of Vitas Healthcare. He holds a JD from the University of Virginia School of Law and a BA from Yale University.

Dwight Crane has been a self-employed consultant to financial institutions since 2007. Previously, he was a faculty member at Harvard Business School. He is also currently the lead director of the Legg Mason Partners Equity Funds. He holds a PhD in economics from Carnegie Mellon University, an MS in economics from Carnegie Mellon, an MBA in management science from the University of Michigan, and a BS from the Massachusetts Institute of Technology.

David Dodd is co-founder of VaxyGen Holdings and CEO of RiversEdge BioVentures, which he also founded. He has previously served as president, CEO, and chairman of BioReliance; non-executive chairman of Stem Cell Sciences; president, CEO, and director of Serologicals Corporation; and president and CEO of Solvay Pharmaceuticals. He is a current director of GeoVax Labs. He holds a BS and an MS in math/economics from Georgia State University and an Advanced Management Program degree from Harvard Business School.

Michael Griffith has served as CEO and a director for Laureate Biopharmaceutical Services since April 2010. Previously, he was founder and CEO of Aptuit. He holds a master's of management from the JL Kellog Graduate School of Management at Northwestern University and a BS in business administration from the University of Kansas.

Jay Hunt is president and co-founder of the Development Group. He is also a director of DDi and BMC Select. Previously he was a member of the advisory board of Joie De Vivre Hospitality, a director of Gentiae Clinical Research, and a chairman of the Ischemia Research & Education Foundation. He holds a JD from the University of Michigan Law School and a BA in political science from Indiana University.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.